```
     FILE 'HCAPLUS' ENTERED AT 08:22:52 ON 29 MAY 2007
L1        311474 S ANTIBODY
L2          4617 S (BETA-GLUCAN)
L3        754497 S CANCER OR TUMOR OR NEOPLAS?
L4        146686 S MONOCLONAL
L5         68113 S GD2 OR CD20 OR EGFR OR HER2 OR NEUROBLASTOMA OR MELANOMA OR L
L6           180 S L1 AND L2
L7            48 S L1 AND L2 AND L3
L8            22 S L1 AND L2 AND L3 AND L4
L9             7 S L1 AND L2 AND L3 AND L4 AND L5

     FILE 'STNGUIDE' ENTERED AT 08:23:03 ON 29 MAY 2007

     FILE 'HCAPLUS' ENTERED AT 08:24:38 ON 29 MAY 2007
L10           81 S L6 AND (PY<2002 OR PRY<2002 OR AY<2002)
L11           18 S L7 AND (PY<2002 OR PRY<2002 OR AY<2002)
L12            3 S L8 AND (PY<2002 OR PRY<2002 OR AY<2002)
L13            1 S L9 AND (PY<2002 OR PRY<2002 OR AY<2002)
```

```
=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.84       0.84

FILE 'HCAPLUS' ENTERED AT 08:22:52 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 May 2007  VOL 146 ISS 23
FILE LAST UPDATED: 28 May 2007  (20070528/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s antibody

L1      311474 ANTIBODY

=> s (beta-glucan)

       1455756 BETA
         14986 GLUCAN
L2        4617 (BETA-GLUCAN)
                 (BETA(W)GLUCAN)

=> s cancer or tumor or neoplas?

        316729 CANCER
        408979 TUMOR
        494653 NEOPLAS?
L3      754497 CANCER OR TUMOR OR NEOPLAS?

=> s monoclonal

L4      146686 MONOCLONAL

=> s GD2 or CD20 or EGFR or HER2 or neuroblastoma or melanoma or lymphona or
epidermoid

          2208 GD2
          3069 CD20
          8590 EGFR
          3603 HER2
         16553 NEUROBLASTOMA
         34665 MELANOMA
             5 LYMPHONA
          2337 EPIDERMOID
L5       68113 GD2 OR CD20 OR EGFR OR HER2 OR NEUROBLASTOMA OR MELANOMA OR
               LYMPHONA OR EPIDERMOID
```

```
=> s L1 and L2

L6          180 L1 AND L2

=> s L1 and L2 and L3

L7           48 L1 AND L2 AND L3

=> s L1 and L2 and L3 and L4

L8           22 L1 AND L2 AND L3 AND L4

=> s L1 and L2 and L3 and L4 and L5

L9            7 L1 AND L2 AND L3 AND L4 AND L5

=> file stnguide

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                2.60       3.44

FILE 'STNGUIDE' ENTERED AT 08:23:03 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 25, 2007 (20070525/UP).

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.18       3.62

FILE 'HCAPLUS' ENTERED AT 08:24:38 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 May 2007  VOL 146 ISS 23
FILE LAST UPDATED: 28 May 2007  (20070528/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s L6 and (PY<2002 or PRY<2002 or AY<2002)

      21897330 PY<2002
       3645664 PRY<2002
```

```
       4174339 AY<2002
L10          81 L6 AND (PY<2002 OR PRY<2002 OR AY<2002)

=> s L7 and (PY<2002 or PRY<2002 or AY<2002)

      21897330 PY<2002
       3645664 PRY<2002
       4174339 AY<2002
L11          18 L7 AND (PY<2002 OR PRY<2002 OR AY<2002)

=> s L8 and (PY<2002 or PRY<2002 or AY<2002)

      21897330 PY<2002
       3645664 PRY<2002
       4174339 AY<2002
L12           3 L8 AND (PY<2002 OR PRY<2002 OR AY<2002)

=> s L9 and (PY<2002 or PRY<2002 or AY<2002)

      21897330 PY<2002
       3645664 PRY<2002
       4174339 AY<2002
L13           1 L9 AND (PY<2002 OR PRY<2002 OR AY<2002)

=> file stnguide

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                2.60       6.22

FILE 'STNGUIDE' ENTERED AT 08:24:51 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 25, 2007 (20070525/UP).

<------User Break------>

=> d L13 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y


L13  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Antitumor antibody-enhancing glucan
AB   This invention provides a composition comprising an effective amount of glucan
     capable of enhancing efficacy of antibodies.  This invention further
     provides the above compns. and a pharmaceutically acceptable carrier.
     This invention also provides a method for treating a subject with
     cancer comprising administrating the above-described composition
     comprising effective amount of glucan capable of enhancing efficacy of
     vaccines.  This invention provides a composition comprising effective amount of
     glucan capable of enhancing efficacy of vaccines.  This invention also
     provides a method of treating a subject comprising administrating the
     above pharmaceutical composition to the subject.  This invention provides a
     composition comprising effective amount of glucan capable of enhancing efficacy
     of natural antibodies.  This invention provides a composition comprising
     effective amount of glucan capable of enhancing host immunity.  This
     invention also provides a composition comprising effective amount of glucan
     capable of enhancing the action of an agent in preventing tissue
     rejection.  It was shown that β-glucans greatly enhanced the
     antitumor effects of monoclonal antibodies against established
```

```
     tumors in mice.
AN   2002:574940  HCAPLUS <<LOGINID::20070529>>
DN   137:119657
TI   Antitumor antibody-enhancing glucan
IN   Cheung, Nai-Kong V.
PA   Sloan-Kettering Institute for Cancer Research, USA
SO   PCT Int. Appl., 114 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   WO 2002058711       A1     20020801    WO 2002-US1276          20020115 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
             UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2434938          A1     20020801    CA 2002-2434938         20020115 <--
     AU 2002241905       A1     20020806    AU 2002-241905          20020115 <--
     EP 1357919          A1     20031105    EP 2002-707502          20020115 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     US 2004116379       A1     20040617    US 2003-621027          20030716 <--
     US 2006020128       A1     20060126    US 2005-218044          20050831 <--
     US 2006160766       A1     20060720    US 2006-334763          20060117 <--
PRAI US 2001-261911P     P      20010116  <--
     WO 2002-US1276      W      20020115
     US 2003-621027      A1     20030716
     WO 2004-US23099     A2     20040716
     US 2005-218044      A2     20050831
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d L12 1-3 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y


L12  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Antitumor antibody-enhancing glucan

L12  ANSWER 2 OF 3  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Clostridial neurotoxin targeted conjugates for inhibition of secretion
     from non-neuronal cells

L12  ANSWER 3 OF 3  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Polymeric drugs based on conjugates of synthetic and natural
     macromolecules. II. Anti-cancer activity of antibody
     or (Fab')2-targeted conjugates and combined therapy with immunomodulators


=> d L12 2 3 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y


L12  ANSWER 2 OF 3  HCAPLUS  COPYRIGHT 2007 ACS on STN
```

TI Clostridial neurotoxin targeted conjugates for inhibition of secretion from non-neuronal cells

AB A method of treatment of disease by inhibition of cellular secretory processes is provided. The method has particular application in the treatment of diseases dependent on the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system, and bone cells. Agents and compns. therefor, as well as methods for manufacturing these agents and compns., are provided. In a preferred embodiment a clostridial neurotoxin, substantially devoid of holotoxin binding affinity for neuronal cells of the presynaptic muscular junction, is associated with a targeting moiety. The targeting moiety is selected such that the clostridial toxin conjugate so formed may be directed to a non-neuronal target cell to which the conjugate may bind. Following binding, a neurotoxin component of the conjugate, which is capable of inhibition of cellular secretion, passes into the cytosol of the target cell by cellular internalization mechanisms. Thereafter, inhibition of secretion from the target cell is effected.

AN 2001:228744 HCAPLUS <<LOGINID::20070529>>

DN 134:247267

TI Clostridial neurotoxin targeted conjugates for inhibition of secretion from non-neuronal cells

IN Foster, Keith Alan; Chaddock, John Andrew; Purkiss, John Robert; Quinn, Conrad Padraig

PA Microbiological Research Authority, UK

SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001021213	A2	20010329	WO 2000-GB3669	20000925 <--
	WO 2001021213	A3	20020711		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2383470	A1	20010329	CA 2000-2383470	20000925 <--
	EP 1235594	A2	20020904	EP 2000-962721	20000925 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003509476	T	20030311	JP 2001-524636	20000925 <--
	AU 782457	B2	20050728	AU 2000-74365	20000925 <--
	US 2003180289	A1	20030925	US 2002-88665	20020814 <--
	AU 2005227383	A1	20051124	AU 2005-227383	20051027 <--
	US 2006216283	A1	20060928	US 2006-327855	20060109 <--
PRAI	GB 1999-22554	A	19990923 <--		
	WO 2000-GB3669	W	20000925 <--		
	WO 2000-GB3681	A	20000925 <--		
	US 2002-88665	A1	20020814		

L12 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')2-targeted conjugates and combined therapy with immunomodulators

AB We provide data on in vivo targeting of the Thy 1.2 (CDw90) cell surface receptor expressed on neoplastic T cells, mouse EL4 T cell lymphoma. The targeting antibody and the anticancer drug,

doxorubicin (DOX) were conjugated to a water-soluble copolymer based on N-(2-hydroxypropyl)methacrylamide (HPMA) acting as a carrier responsible for controlled intracellular release of the conjugated drug. The in vivo therapeutic efficacy of HPMA copolymer-bound DOX targeted with anti-EL4 antibody, polyclonal anti-thymocyte globulin (ATG), monoclonal anti-Thy 1.2 antibody or its F(ab')2 fragment was compared with the efficacy of DOX conjugated to HPMA copolymer containing nonspecific IgG or bovine serum albumin (BSA). Anti-EL4 antibody -targeted conjugate caused a significant retardation of tumor growth and an extension of the life span of treated mice. The effect was comparable with that of HPMA copolymer-bound DOX targeted with ATG, anti-Thy 1.2 antibody or its F(ab')2 fragment. However, considerable antitumor effect was seen also in conjugates targeted instead of specific antibodies with syngeneic nonspecific IgG or BSA. Patients with advanced cancer are often immunocompromised due to dysfunction of their immune system induced by cancer and cytotoxic drugs. A significant decrease of unwanted side-effects of targeted drugs against a number of vital organs was already documented. In this study we have compared immunotoxic effects of free DOX with those of its antibody-targeted form on NK cells and cytolytic T lymphocytes (CTLs) isolated from C57BL/10 mice bearing EL4 T cell lymphoma. In the same model we have tested the combination therapy with immunomodulators (β -glucan or AM-2) injected together with targeted daunomycin. We have observed a significant protective effect of targeted DOX against NK cells and CTLs. Moreover, the data revealed that combination therapy considerably enhances antitumor efficacy of the targeted anticancer drug.

AN 2000:46595 HCAPLUS <<LOGINID::20070529>>
DN 132:284054
TI Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')2-targeted conjugates and combined therapy with immunomodulators
AU Rihova, B.; Jelinkova, M.; Strohalm, J.; Subr, V.; Plocova, D.; Hovorka, O.; Novak, M.; Plundrova, D.; Germano, Y.; Ulbrich, K.
CS Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, 142 20, Czech Rep.
SO Journal of Controlled Release (2000), 64(1-3), 241-261
CODEN: JCREEC; ISSN: 0168-3659
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l11 1-18 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L11 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Therapy-enhancing glucan

L11 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Macrophage receptor Dectin-1

L11 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Antitumor antibody-enhancing glucan

L11 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Plants, polysaccharides, and the treatment and prevention of neoplasia

L11 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Clostridial neurotoxin targeted conjugates for inhibition of secretion from non-neuronal cells

L11 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of antibody against antitumor β - glucan in Grifola frondosa and its application

L11 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Immunopharmacological and immunotoxicological activities of a water-soluble (1 → 3)-β-D-glucan, CSBG from Candida spp

L11 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Failure in antitumor activity by overdose of an immunomodulating . beta.-glucan preparation, sonifilan

L11 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')2-targeted conjugates and combined therapy with immunomodulators

L11 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Antigen-specific response of murine immune system toward a yeast . beta.-glucan preparation, zymosan

L11 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Activation of murine macrophages by grifolan

L11 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Cellular requirements for immunomodulatory effects caused by cell wall components of Paracoccidioides brasiliensis on antibody production

L11 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation and specificity of antibodies to an anti-tumor . beta.-glucan, lentinan

L11 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Covalently bound β -glucan conjugates with bioactive agents for targeted delivery

L11 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Interrelation of structure and antitumor effects of fungal (1→3) β-D-glucans.

L11 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Pulmonary metastases neutralization and tumor rejection by in vivo administration of β glucan and bispecific antibody

L11 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Straw mushroom, fukurotake, Volvariella volvacea

L11 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Antitumor and immunomodulating activities of a β - glucan obtained from liquid-cultured Grifola frondosa

=> d l11 4 6 7 8 10 11 13 14 16 17 18 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L11 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Plants, polysaccharides, and the treatment and prevention of

neoplasia
AB A review. Plants and Fungi have traditionally been the single largest source of lead compds. for the development of therapeutics by the pharmaceutical industry. Currently mushroom and plant polysaccharides brought to attention by Complementary and Alternative medicine, are undergoing scientific anal. and development to prevent and treat cancer. Two classes of saccharides are under investigation- beta glucan polysaccharides as biol. response modifiers for the adjuvant treatment of cancer and "Oligosaccharin"- related oligosaccharides for the prevention of sun-induced skin cancer. Beta glucans already in human trials in the Far East will require mechanistic pharmacol. studies and definition of structure function relationships before they are ready for clin. trials in the West. Other beta glucans that prime natural killer cells for antibody dependent cell-mediated cytotoxicity are approaching clin. trials. Oligosaccharides that downregulate production of immuno-suppressive cytokines by UV radiation injured keratinocytes are promising agents for the prevention of environmental skin cancer.
AN 2001:398732 HCAPLUS <<LOGINID::20070529>>
DN 136:160666
TI Plants, polysaccharides, and the treatment and prevention of neoplasia
AU Pelley, Ronald P.; Strickland, Faith M.
CS Pangea Phytoceuticals, Harlingen, TX, 78550, USA
SO Critical Reviews in Oncogenesis (2000), 11(3&4), 189-225
CODEN: CRONEI; ISSN: 0893-9675
PB Begell House, Inc.
DT Journal; General Review
LA English
RE.CNT 197 THERE ARE 197 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of antibody against antitumor β - glucan in Grifola frondosa and its application
AB Antibodies against an antitumor β -glucan purified from Grifola frondosa (GGF) were raised in the rabbit by s.c. immunization. Our antibodies reacted significantly with GGF by an ELISA inhibition assay. The antibodies did not recognize other polysaccharides such as laminarin and pustulan, but reacted somewhat with lentinan, whose structure is similar to GGF. It was demonstrated that GGF could be measured by ELISA using antibodies. In addition, the effects of the storage temperature on GGF content during storage were measured using our antibody. GGF content was 24.7 μg/g fresh weight (f.w.) at zero time storage, and little change occurred during storage of the mushroom for 7 days at 5°. However, a drastic decrease to 11.4 μg/g f.w. occurred after 7 days of storage at 20°. These results suggest that storage at low temps. is desirable to maintain the quality of GGF.
AN 2000:308382 HCAPLUS <<LOGINID::20070529>>
DN 133:320973
TI Preparation of antibody against antitumor β - glucan in Grifola frondosa and its application
AU Mizuno, Masashi; Yamakawa, Akio; Minato, Ken-Ichiro; Kawakami, Sachiko; Tatsuoka, Shigenobu; Terai, Hirofumi; Tsuchida, Hironobu
CS Graduate School of Science and Technology, Kobe University, Kobe, 657-8501, Japan
SO Food Science and Technology Research (1999), 5(4), 398-401
CODEN: FSTRFS; ISSN: 1344-6606
PB Japanese Society for Food Science and Technology
DT Journal
LA English
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Immunopharmacological and immunotoxicological activities of a water-soluble (1 → 3)-β-D-glucan, CSBG from Candida spp
AB We have established a convenient, two-step procedure to solubilize the yeast cell wall (1→3)-β-D-glucan using the combination of NaClO oxidation and DMSO extraction Candida soluble β-D-glucan (CSBG) was mainly composed of a linear β-1,3 glucan with a linear β-1,6-glucan moiety. In this study, we screened for several immunopharmacol. activities of CSBG and found the following activities: (1) interleukin-6 synthesis of macrophages in vitro; (2) antagonistic effect for zymosan mediated-tumor necrosis factor synthesis of macrophages; (3) augmentation for lipopolysaccharide mediated tumor necrosis factor and nitrogen oxide syntheses of macrophages; (4) activation of alternative pathway of complement; (5) hematopoietic response on cyclophosphamide induced leukopenia; (6) the antitumor effect on ascites form tumor; (7) Enhanced vascular permeability; (8) priming effect on lipopolysaccharide triggered TNF-α synthesis; and (9) adjuvant effect on antibody production These results strongly suggested that CSBG possessed various immunopharmacol. activity.
AN 2000:235041 HCAPLUS <<LOGINID::20070529>>
DN 133:12504
TI Immunopharmacological and immunotoxicological activities of a water-soluble (1 → 3)-β-D-glucan, CSBG from Candida spp
AU Tokunaka, Kazuhiro; Ohno, Naohito; Adachi, Yoshiyuki; Tanaka, Shigenori; Tamura, Hiroshi; Yadomae, Toshiro
CS Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, 192-0392, Japan
SO International Journal of Immunopharmacology (2000), 22(5), 383-394
CODEN: IJIMDS; ISSN: 0192-0561
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Failure in antitumor activity by overdose of an immunomodulating . beta.-glucan preparation, sonifilan
AB Schizophyllan (SPG, Sonifilan) is a soluble (1→3)-β-D-glucan, used as a biol. response modifier (BRM) with radiation therapy for cancer treatment in Japan. The mechanism of SPG-mediated antitumor activity is thought to be via immune stimulation, which includes cytokine production, hematopoietic response, and so on. In this paper, we found that the activity of SPG was quite long-lived and an overdose significantly failed to display the antitumor activity. To demonstrate the mechanism several parameters were examined using a high dose of SPG administration as follows: i) the effect on vascular permeability in vivo, ii) the priming effect on tumor necrosis factor (TNF-α) production in vivo, iii) the effect on macrophage adherence to plastic plate in vitro, and iv) anti-Sarcoma 180 antibody production in vivo. It was evident that vascular permeability and anti-Sarcoma 180 antibody production remained unchanged, but TNF-α production and adherence to a plastic plate was significantly reduced by a high dose of SPG. These facts strongly suggested that modulation of the cytokine syntheses and the leukocyte traffic would be the causative mechanisms of the failure of antitumor activity by an overdose of SPG.
AN 2000:97854 HCAPLUS <<LOGINID::20070529>>
DN 132:245973
TI Failure in antitumor activity by overdose of an immunomodulating . beta.-glucan preparation, sonifilan
AU Miura, Toshihide; Miura, Noriko N.; Ohno, Naohito; Adachi, Yoshiyuki; Shimada, Shigehiko; Yadomae, Toshiro

CS Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, 192-0392, Japan
SO Biological & Pharmaceutical Bulletin (2000), 23(2), 249-253
CODEN: BPBLEO; ISSN: 0918-6158
PB Pharmaceutical Society of Japan
DT Journal
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Antigen-specific response of murine immune system toward a yeast .beta.-glucan preparation, zymosan
AB Zymosan, a particulate β -glucan preparation from Saccharomyces cerevisiae, shows various biol. activities, including anti-tumor activity. We have previously shown that soluble .beta .-glucan initiated anti-tumor activity was long-lived and was effective even by prophylactic treatment at 1 mo prior to tumor challenge. However, the activity by zymosan was relatively short-lived. Antigen-specific responses of mice to zymosan might be a causative mechanism. In this paper, mice were immunized with zymosan and antibody production and antigen-specific responses of lymphocytes to zymosan were analyzed. Sera of zymosan immune mice contained zymosan-specific IgG assessed by ELISA and FACS. Spleen and bone marrow cells of zymosan-immune mice showed higher cytokine production in response to zymosan. Specificity of zymosan-specific responses were also analyzed using various derivs. prepared from zymosan. These facts strongly suggested that mice recognize zymosan as antigen in addition to non-specific immune stimulant.
AN 1999:311543 HCAPLUS <<LOGINID::20070529>>
DN 131:128740
TI Antigen-specific response of murine immune system toward a yeast .beta.-glucan preparation, zymosan
AU Miura, T.; Ohno, N.; Miura, N. N.; Adachi, Y.; Shimada, S.; Yadomae, T.
CS School of Pharmacy, Laboratory for Immunopharmacology of Microbial. Products, Tokyo University of Pharmacy and Life Science, Hachioji, Tokyo, 192-0392, Japan
SO FEMS Immunology and Medical Microbiology (1999), 24(2), 131-139
CODEN: FIMIEV; ISSN: 0928-8244
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Activation of murine macrophages by grifolan
AB A gel-forming (1→3)-β-D-glucan, grifolan (GRN) from an edible mushroom (Grifola frondosa), enhances various immunol. activities. Here, effect of GRN on the induction of cytokines and nitric oxide by macrophage (MP) cell line (RAW264.7), peritoneal MP (PM), and Kupffer cell is shown. GRN bound to MP was detected immunohistochem., using an anti-GRN antibody. GRN could induce production of TNFα, IL-1α, and IL-6 by RAW264.7. Incubation with GRN also induced those cytokines in PM. GRN induced phosphorylation of MAP kinase and p38 of PM. The kinetic study on the activation of Kupffer cells revealed that GRN could induce enhanced production of cytokines and nitric oxide on days 4-7 after i.v. administration of GRN. Cytostatic activity of Kupffer cells against murine lymphoma, EL-4, was also augmented by GRN with similar time course to nitric oxide production The cytostatic activity was dependent on nitric oxide, since an iNOS inhibitor diminished the cytostatic activity. Administration of GRN increased expression of CD11b, known as the .beta.-glucan receptor, on Kupffer cells on day 7.

Apparently, GRN can activate murine MPs to enhance production of cytokines and nitric oxide.

AN 1998:453248 HCAPLUS <<LOGINID::20070529>>
DN 129:211409
TI Activation of murine macrophages by grifolan
AU Adachi, Y.; Takano, E.; Ohno, N.; Yadomae, T.
CS School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan
SO Proceedings - Beltwide Cotton Conferences (1998), (Vol. 1), 262-266
CODEN: PCOCEN; ISSN: 1059-2644
PB National Cotton Council
DT Journal
LA English
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation and specificity of antibodies to an anti-tumor . beta.-glucan, lentinan
AB Antibodies against β -glucan, lentinan from "Shittake" (Lentinus edodes), were raised in the rabbit by s.c. immunization. Our antibodies reacted significantly with lentinan by inhibition assay of ELISA. The antibodies did not recognize the other polysaccharides such as amylose, dextran, laminarin and galactan. It was proved that lentinan contents in mushroom could be measured by ELISA with the anti-lentinan antisera. Its contents were 3.5 mg/g fresh weight in Lentinus edodes. However, lentinan was not contained in Agaricus brazei, Agaricus bisporus and Romania bitrytis.
AN 1997:90871 HCAPLUS <<LOGINID::20070529>>
DN 126:170161
TI Preparation and specificity of antibodies to an anti-tumor . beta.-glucan, lentinan
AU Mizono, Masashi; Minato, Ken-ichiro; Tsuchida, Hironobu
CS Grad. Sch. Sci. and Tech., Kobe Univ., Kobe, 657, Japan
SO Biochemistry and Molecular Biology International (1996), 39(4), 679-685
CODEN: BMBIES; ISSN: 1039-9712
PB Academic
DT Journal
LA English

L11 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Covalently bound β -glucan conjugates with bioactive agents for targeted delivery
AB A glucan composition is disclosed which contains a β-1,3-glucan covalently attached to a bioactive agent. The β-1,3-glucan is attached to the bioactive agent by means of a hydrolyzable covalent linkage to form a glucan/agent complex. Also disclosed are methods relating to the complex of the invention, including a method for the treatment of a pathogen capable of invading or colonizing phagocytic cells, and a method for delivering an antigen to a phagocytic cell. Purification of glucan from Euglena gracilis is described. Also described is e.g. preparation of a β-1,3-glucan conjugate with herpes simplex virus gD2 glucoprotein. The conjugate had enhanced adjuvant activity.
AN 1996:462438 HCAPLUS <<LOGINID::20070529>>
DN 125:105156
TI Covalently bound β -glucan conjugates with bioactive agents for targeted delivery
IN Tuse, Daniel; Mohagheghpour, Nahid; Dawson, Marcia; Hobbs, Peter; Winant, Richard
PA Sri International, USA
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9614873	A2	19960523	WO 1995-US14800	19951114 <--
	WO 9614873	A3	19960829		

W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1994-340831 A 19941116 <--

L11 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Pulmonary metastases neutralization and tumor rejection by in vivo administration of β glucan and bispecific antibody
AB Bispecific antibody (BsAb) with specificity for tumor cell surface antigen and the CD3 mol. on T cells can redirect activated T cells to lyse tumor cells. Since the ex vivo expansion and activation of T cells is impractical and ineffective for treating established tumors, the authors tested whether the immune stimulant . beta. glucan could in situ-activate T cells, which could secondarily be retargeted with BsAbs to lyse tumor cells. To test for tumor neutralization, C3H/HeN mice were injected i.v. with Cl-62 melanoma cells and immediately treated with i.p. .beta . glucan and/or anti-CD3 (500A2) + anti-p97 (96.5) F(ab')2 BsAb i.v. Pulmonary metastases were counted 14 days later. To test for tumor rejection and survival in a solid tumor model, mice were injected s.c. and i.p. with Cl-62 cells and 7 days later administered β glucan i.p. and/or F(ab')2 BsAb i.v. In the neutralization model, there was a significant reduction in the number of metastases in the β glucan + BsAb group, as compared with controls, and with β glucan alone. In the established tumor model, β glucan + BsAb reduced the incidence of s.c. tumors as compared with control, BsAb alone, and β glucan alone. It also prolonged survival of tumor-bearing mice compared with control, BsAb alone, and β glucan alone. Thus, T cells can be activated in vivo by β glucan and retargeted with F(ab')2 BsAb.
AN 1996:160223 HCAPLUS <<LOGINID::20070529>>
DN 124:257967
TI Pulmonary metastases neutralization and tumor rejection by in vivo administration of β glucan and bispecific antibody
AU Penna, Christophe; Dean, Phillip A.; Nelson, Heidi
CS Department Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN, 55905, USA
SO International Journal of Cancer (1996), 65(3), 377-82
CODEN: IJCNAW; ISSN: 0020-7136
PB Wiley-Liss
DT Journal
LA English

L11 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Straw mushroom, fukurotake, Volvariella volvacea
AB A review with 14 listed refs. on the systematic fractionation and structural diversity of branched (1→3)- β, - glucan of fukurotake, chemical modification in relation to immunomodulating mechanism of the glucans, antibodies to the glucans and their application in studies of neoplasm inhibition.
AN 1995:536205 HCAPLUS <<LOGINID::20070529>>
DN 123:141915
TI Straw mushroom, fukurotake, Volvariella volvacea
AU Misaki, Akira; Kishida, Etsu

CS Osaka City University, Ashiya, 659, Japan
SO Food Reviews International (1995), 11(1), 219-23
CODEN: FRINEL; ISSN: 8755-9129
DT Journal; General Review
LA English

L11 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Antitumor and immunomodulating activities of a β - glucan obtained from liquid-cultured Grifola frondosa
AB The effects of the β-1,3-glucan, LELFD, obtained from liquid-cultured mycelium of G. frondosa, on the growth of syngeneic tumors and immune responses in mice were examined In Meth A fibrosarcoma or IMC carcinoma solid tumor systems, LELFD administered i.p. or intralesionally (i.l.) exhibited significant antitumor effects. However, the growth of L1210 and P388 leukemias was unaffected by the injection of LELFD. The injection of LELFD i.p. enhanced the activities of natural killer cells and macrophages in mice. LELFD also enhanced the antibody response when it was injected i.p. with sheep red blood cells into mice. Furthermore, it was found that LELFD could activate complement pathway.
AN 1989:185485 HCAPLUS <<LOGINID::20070529>>
DN 110:185485
TI Antitumor and immunomodulating activities of a β - glucan obtained from liquid-cultured Grifola frondosa
AU Suzuki, Iwao; Hashimoto, Koichi; Oikawa, Shozo; Sato, Kichiro; Osawa, Masumi; Yadomae, Toshiro
CS Tokyo Coll. Pharm., Hachioji, 192-03, Japan
SO Chemical & Pharmaceutical Bulletin (1989), 37(2), 410-13
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	66.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.92

FILE 'CAPLUS' ENTERED AT 08:28:15 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 May 2007 VOL 146 ISS 23
FILE LAST UPDATED: 28 May 2007 (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l11 and oral
        311474 ANTIBODY
       1455756 BETA
         14986 GLUCAN
          4617 (BETA-GLUCAN)
                 (BETA(W)GLUCAN)
        316729 CANCER
        408979 TUMOR
        494653 NEOPLAS?
      21897330 PY<2002
       3645664 PRY<2002
       4174339 AY<2002
        207085 ORAL
L14          1 L11 AND ORAL

=> d l14 ti

L14  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Therapy-enhancing glucan


=> d his

     (FILE 'HOME' ENTERED AT 08:20:33 ON 29 MAY 2007)

     FILE 'HCAPLUS' ENTERED AT 08:22:52 ON 29 MAY 2007
L1       311474 S ANTIBODY
L2         4617 S (BETA-GLUCAN)
L3       754497 S CANCER OR TUMOR OR NEOPLAS?
L4       146686 S MONOCLONAL
L5        68113 S GD2 OR CD20 OR EGFR OR HER2 OR NEUROBLASTOMA OR MELANOMA OR L
L6          180 S L1 AND L2
L7           48 S L1 AND L2 AND L3
L8           22 S L1 AND L2 AND L3 AND L4
L9            7 S L1 AND L2 AND L3 AND L4 AND L5

     FILE 'STNGUIDE' ENTERED AT 08:23:03 ON 29 MAY 2007

     FILE 'HCAPLUS' ENTERED AT 08:24:38 ON 29 MAY 2007
L10          81 S L6 AND (PY<2002 OR PRY<2002 OR AY<2002)
L11          18 S L7 AND (PY<2002 OR PRY<2002 OR AY<2002)
L12           3 S L8 AND (PY<2002 OR PRY<2002 OR AY<2002)
L13           1 S L9 AND (PY<2002 OR PRY<2002 OR AY<2002)

     FILE 'STNGUIDE' ENTERED AT 08:24:51 ON 29 MAY 2007

     FILE 'HCAPLUS' ENTERED AT 08:25:06 ON 29 MAY 2007

     FILE 'STNGUIDE' ENTERED AT 08:25:07 ON 29 MAY 2007

     FILE 'HCAPLUS' ENTERED AT 08:25:17 ON 29 MAY 2007

     FILE 'STNGUIDE' ENTERED AT 08:25:17 ON 29 MAY 2007

     FILE 'HCAPLUS' ENTERED AT 08:25:34 ON 29 MAY 2007

     FILE 'STNGUIDE' ENTERED AT 08:25:35 ON 29 MAY 2007

     FILE 'HCAPLUS' ENTERED AT 08:26:36 ON 29 MAY 2007

     FILE 'STNGUIDE' ENTERED AT 08:26:37 ON 29 MAY 2007

     FILE 'HCAPLUS' ENTERED AT 08:28:09 ON 29 MAY 2007
```

FILE 'STNGUIDE' ENTERED AT 08:28:10 ON 29 MAY 2007

FILE 'CAPLUS' ENTERED AT 08:28:15 ON 29 MAY 2007
L14 1 S L11 AND ORAL

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.91	87.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.92

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:28:33 ON 29 MAY 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 09:32:29 ON 29 MAY 2007
FILE 'CAPLUS' ENTERED AT 09:32:29 ON 29 MAY 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.91	87.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.92

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.38	87.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.92

FILE 'HCAPLUS' ENTERED AT 09:33:04 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

strictly prohibited.

FILE COVERS 1907 - 29 May 2007 VOL 146 ISS 23
FILE LAST UPDATED: 28 May 2007 (20070528/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s oral

L15   207085 ORAL

=> s L10 and L15

L16   3 L10 AND L15

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	90.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.92

FILE 'STNGUIDE' ENTERED AT 09:33:20 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 25, 2007 (20070525/UP).

=> d l16 1-3 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L16 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI   Therapy-enhancing glucan

L16 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI   Immortal cell line derived from the grouper Epinephelus coioides and the applications thereof

L16 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI   Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti HSP90 antibodies

=> d l16 2 3 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L16 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI   Immortal cell line derived from the grouper Epinephelus coioides and the applications thereof
AB   The invention comprises the generation of antibodies against nervous necrosis virus (NNV) and infectious pancreatic necrosis (IPNV) virus. The